NICE is a world-renowned, independent organisation responsible for providing national recommendations on the use of new and existing medicines and treatments within the NHS, through the Technology Appraisal Programme. The Scientific Advice Programme provides not-for-profit chargeable consulting services to companies who have products in development that may be referred for future evaluation by NICE.
New drug formulations, biological agents, combination therapies and the latest pharmaceutical developments designed to improve outcomes in patients with a wide range of cancers were highlighted at EMCC 2001. Here are just a few of the highlights:
Science is always at its most exciting when it looks to the far horizons. And the unavoidably controversial yet incredibly promising area of stem cell science provides arguably one of the most apt examples.
Esther Dyson the Great Dame of Silicon Valley, at times matriarch to Bill Gates and many other lads on the innovative circuit, wrote a harsh column August 26th on GPS CNN on ICANN gTLD. I like and respect Esther especially her technical background, we have shared the podium, but as this topic deals with the centrality of global corporate nomenclature it demands an authoritative analysis and I feel itâs my responsibility to clarify and taken the liberty to address her entire piece item by item.
For recent graduates from science, medicine, or mathematics programs, applying for work in the ever-expanding pharmaceutical industry can be an intelligent choice for both career and financial stability. Depending on the industry upon which you choose to focus, the rules and expectations during the interview process can vary.
Almost irrespective of the country you live in, the increasing costs of healthcare are unavoidable. For governments, the stresses are particularly acute, as both aging populations and the increasing cost of treatments add financial pressures year on year. Yet as a new study by the Institute of Fiscal Studies (IFS) confirms, we should not underestimate the extent to which the shape of the state has already changed.
Max Golby - PharmiWeb Field Reporter
At a moment when the national discourse on international aid is grounded in pessimism, David Cameronâs pledge to commit ÂŁ814m to help vaccinate the worldâs poorest children provides an necessary reminder of what international aid really can achieve.
Certolizumab pegol (Cimzia ÂŽ) delivered rapid and consistent improvements in a broad range of rheumatoid arthritis (RA) patients after 12 weeks of treatment regardless of whether or not they had received prior TNF inhibitors or whether or not they were receiving concomitant DMARDs, concluded the latest analysis of the Phase III b REALISTIC trial presented at the European League Against Rheumatism (EULAR) meeting in London, May 25-28 (abstract FRI021).
Both drugs are protease inhibitors (PIs) and are designed to block an enzyme that helps the hepatitis C virus replicate. Hepatitis C is a liver disease caused by infection with the hepatitis C virus, which is transmitted through contaminated blood. The infection can cause liver failure and liver cancer.
Rhonda Siddall-Freelance Medical Journalist and Writer
Brand managers and marketing leads are always striving to gain that first step of engagement, particularly in our world of pharmaceutical manufacturing. And with good reason. Customer engagement leads to improved understanding, which drives loyalty and ultimately improved health.
Eric Boothe, Director Business DevelopmentâLife Sciences
Since the very dawn of Western capitalism, competition has been synonymous with success. Indeed, in accounting for the past 500 years of Western ascendancy in the world, Professor Niall Ferguson of Harvard University points to six âkiller appsâ. The first of these, unsurprisingly, is competition
Earlier this month the UK drugs giant GlaxoSmithKline announced a groundbreaking and progressive new scheme for graduates, whereby from 2012 the company will offer to reimburse in full the university tuition fees of the entirety its future graduate intake.
After six months of sometimes lively pursuit, the French pharmaceutical group, Sanofi-aventis, has agreed a deal to pay $20.1bn in cash for U.S. biotech firm Genzyme Corp after Sanofi made an increased offer of $74 per share.
Max Golby - PharmiWeb Field Reporter
Social networking sites such as Facebook, Linkedin and Twitter are all the rage â thereâs no escaping them, theyâre everywhere â even in the workplace, and whether you like it or not, theyâre not going away.
Catherine Gutsell, CK Group
If you are new to using PharmiWeb.com to find a new job, you'll soon realise that we have thousands of jobs listed and that they change every day. This means you may initially find the task a bit daunting.
However, itâs not really that hard, and with a bit of thought, you will soon be asking why you didnât do it years ago.
When David Cameron recently found himself in the hot seat on the BBCâs Andrew Marr Show, one policy area brought challenges beyond all others. Healthcare reform, Mr. Marr suggested in a short exchange, is swiftly becoming a major source of controversy for this government.
As a result of a vote taken in the European Parliament earlier this week, patients in the European Union will receive improved information on prescription drugs, in addition to being protected from some of the more potentially exploitable clauses of the Commissionâs proposed Directive on Information to Patients.
In an age of competition and choice, patient knowledge is paramount. Between 1997 and 2007, the Blair governmentâs entire programme of public sector reforms were delivered under the banner of âChoice and Competitionâ.
With the global economy remaining stagnant, big pharma companies are keen to develop blockbuster drugs that have a high financial ceiling. Rodger McMillan, VP of R&D at Astra Zeneca has said that âbig pharma is a cash-rich industry â it has to be,â namely because of the huge costs in developing new drugs â sometimes as much as $200 million.
In the USA alone, when your neighbor is out of work it is a slowdown, when your
family member is added it becomes recession and when you too join the same line
than it surely becomes a depression. The unofficial employment in USA being claimed at 15-25 percent while the economical turnaround seems a mirage; the closer you get the clearer becomes the reality, nothing but refractions.
In many ways, the National Institute for Health and Clinical Excellence (NICE) embodies many of the characteristics that define the NHS. In a system of universal access â and in a world where resources are finite â tough decisions inevitably have to be made. And by taking difficult decisions, particularly in reference to end of life care, NICE attempts to make the most of the drugs budget we do have.
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her